Pinterest
Sun Pharma announces USFDA approval for generic Namenda® tablets	   	Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.

Sun Pharma announces USFDA approval for generic Namenda® tablets Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets and Imatinib Mesylate tablets,

Sun Pharmaceutical Industries Ltd’s southward journey continues for yet another trading session. The scrip is currently trading 1.3% lower at Rs. 709.15 on BSE, which is a 16-month low level. - See more at: http://ways2capital-equitytips.blogspot.in/2015/11/sun-pharma-falls-13-pays-rs-500-cr.html#sthash.7RMIbaax.dpuf

Sun Pharma rallies over after strong numbers : Sun Pharma reported an over two-fold jump in its consolidated net profit to Rs crore for the September quarter.

India’s largest drugmaker Sun Pharmaceutical Industries Ltd said it had received a warning letter from the US Food and Drug Administration for violating manufacturing standards at its Halol plant in western India. The warning indicates the agency is not satisfied with the remedial measures Sun Pharma has been taking at the plant since last September …

India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U. sales might fall this year because of pressure on .

Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf

Medical professional’s wits against the genes of bacteria: The world’s newest threat, antibiotic resistant bugs, with the unaffectionate sobriquet ‘superbugs,’ are getting the better of the medical and pharmaceutical fraternity.

Shares of Sun Pharmaceutical Industries Ltd are currently trading 1.50% higher at Rs. 770.35 on BSE after it was reported by a financial daily that the company will raise Rs. 1,000 crore from the domestic bond market via its arm Sun Laboratories.

Shares of Sun Pharmaceutical Industries Ltd are currently trading higher at Rs. on BSE after it was reported by a financial daily that the company will raise Rs. crore from the domestic bond market via its arm Sun Laboratories.

Sun Pharmaceutical Industries Ltd ended 2.8% higher at Rs. 777.3 after the US drug regulator gave a green signal to the company’s generic Gleevec drug.

Sun Pharmaceutical Industries Ltd ended higher at Rs. after the US drug regulator gave a green signal to the company’s generic Gleevec drug.

Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …

the FDA just banned all imports from Sun Pharmaceuticals, makers of Modalert

#SunPharmaceutical Industries Ltd wins U.S. approval to buy #Ranbaxy  http://pocketnewsalert.blogspot.in/2015/01/sun-pharmaceutical-industries-ltd-wins.html

India's Sun Pharmaceutical Industries Ltd has won U. approval to buy Ranbaxy Laboratories Ltd on condition

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 849, up by 8.6 points or 1.02% from its previous closing of Rs. 839.7 - See more at: http://ways2capital-equitytips.blogspot.in/2015/09/sun-pharmaceutical-may-divest.html#sthash.CPXETRiL.dpuf

Shares of Sun Pharmaceutical Industries, India’s largest drug maker, are currently trading lower at Rs. on BSE. The company has singed a global deal with ICGEB for treatment of Dengue.

Shares of Sun Pharmaceuticals Industries Ltd are currently trading 2.19% lower at Rs. 742.15 on BSE despite the company announcing research collaborations with two world-class universities in the area of neurological diseases. - See more at: http://ways2capital-equitytips.blogspot.in/2015/12/sun-pharma-inks-research-pact-with.html#sthash.F2CcJvlm.dpuf

Shares of Sun Pharmaceuticals Industries Ltd are currently trading lower at Rs. on BSE despite the company announcing research collaborations with two world-class universities in the area of neurological diseases.

Sun Pharmaceutical Industries Ltd has announced the following consolidated results for the quarter ended June 30, 2016:

Sun Pharma ended lower at on BSE. The pharma company received a Warning Letter from the US FDA as a result of the September 2014 inspection, for its facility located at Halol, Gujarat in India.

Sun Pharmaceutical Industries Ltd. has recalled 68,000 bottles of the antidepressant Effexor in the U.S., in the second recall of the drug this year, the U.S. Food and Drug Administration said http://online.wsj.com/articles/sun-pharma-recalls-effexor-in-u-s-1416297616?mod=WSJ_LatestHeadlines

Sun Pharma Recalls Effexor in U.S.

India's Sun Pharma recalls over bottles of antidepressant ! they dump their "failures" on the so-called third world, just as they've did with tobacco products.